English hospitals report shortages of aspirin and other common medicines


Hospital responses describe prolonged painkiller shortages and higher spending to secure a blood-pressure drug. The figures cover responding trusts, not hospitals nationwide.
Hospitals in England reported difficulty obtaining aspirin, co-codamol and ramipril in findings published by the Guardian on 29 September. Aspirin disruption was the most common among the trusts that answered questions about each medicine. Some co-codamol shortages lasted months, while one trust paid more for ramipril to keep supplies uninterrupted.
The findings came from freedom-of-information requests by Dr Rodolfo Catena, a University College London researcher specialising in health supply chains. NHS trusts—the organisations that run health services—were asked about stocks of the three medicines. Only 60 of the 184 trusts approached responded, and fewer answered each drug-specific question. These figures therefore do not establish how widespread shortages were across England.
| Medicine and use | Trusts reporting disruption | Period covered |
|---|---|---|
| Aspirin: pain relief and reducing blood-clot risk | 26 of 42 respondents | December 2025–March 2026 |
| Co-codamol: paracetamol and codeine combined for pain relief | 13 of 42 respondents | Different periods in individual hospital accounts, described below |
| Ramipril: treatment for high blood pressure | 7 of 43 respondents | The time span covered is unclear |

York and Scarborough NHS trust reported that its co-codamol supply had been disrupted since May 2025. Royal Wolverhampton NHS trust struggled to obtain enough between October 2025 and August 2026—a period the Guardian described as 10 months.
Frimley Health NHS trust, which serves people in Surrey, Berkshire and Buckinghamshire, paid higher prices for ramipril to maintain uninterrupted supplies rather than risk disruption affecting patients, Catena found. This documents an additional procurement cost, not a treatment delay. The hospital findings do not quantify how many patients, if any, had treatment delayed by the shortages.
In a Guardian letter published on 5 October, Amanda Cole, identified as director of the Office of Health Economics, argued that driving prices for medicines no longer protected by patents unsustainably low can push manufacturers out of the market. Fewer suppliers, she said, leave the remaining supply more vulnerable to disruption or a jump in demand. She called for pricing and regulatory decisions that balance affordability with suppliers’ ability to maintain reliable supplies. This is her argument about the wider market, not an established explanation for the shortages at these trusts.
In its response published on 29 September, the Department of Health and Social Care acknowledged that ramipril was in limited supply. A spokesperson said the department had issued serious shortage protocols—measures intended to help UK patients obtain the medication they need. The department said the vast majority of licensed medicines remained in good supply and that it was working with suppliers to resolve the problems affecting ramipril, co-codamol and aspirin.
The light-control technique was used with gene delivery and special goggles in a vision trial. The result in one man does not establish a generally effective treatment.
3 min

The agency reports no evidence of ongoing transmission, but the unconfirmed diagnosis prevents it from judging whether Russia’s seven-day contact monitoring was sufficient.
8 min

A Tohoku University experiment found gains on later days in an eye-movement task. Rhythmic changes in brain blood volume were associated with better learning, but have not been shown to cause it.
2 min